La rosiglitazone, commercialisée sous le nom d'Avandia (r), fait partie d'une classe d'antidiabétique oral apparue sur le marché en 2002 : les thiazolidinediones.Son autorisation de mise sur le marché (AMM) a été suspendue en France et en Europe en septembre 2010 en raison d'importants risques cardiovasculaires.

PropertyValue
dbpedia-owl:abstract
  • La rosiglitazone, commercialisée sous le nom d'Avandia (r), fait partie d'une classe d'antidiabétique oral apparue sur le marché en 2002 : les thiazolidinediones.Son autorisation de mise sur le marché (AMM) a été suspendue en France et en Europe en septembre 2010 en raison d'importants risques cardiovasculaires. Aux États-Unis, son utilisation a été fortement restreinte par la Food and Drug Administration (FDA) pour les mêmes raisons.
  • Rozyglitazon (roziglitazon, rosiglitazon, rosiglitazone ATC A10BG) – należący do doustnych leków hipoglikemizujących (grupa tiazolidinedionów), lek stosowany w leczeniu cukrzycy.
  • Росиглитазон — лекарственное средство, гипогликемический препарат из группы тиазолидиндионов, селективный агонист ядерных рецепторов PPAR-гамма.
  • Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis published in the New England Journal of Medicine in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.Despite rosiglitazone's effectiveness at decreasing blood sugar in type 2 diabetes mellitus, its use decreased dramatically as studies showed apparent associations with increased risks of heart attacks and death. Adverse effects alleged to be caused by rosiglitazone were the subject of over 13,000 lawsuits against GSK; as of July 2010, GSK had agreed to settlements on more than 11,500 of these suits.Some reviewers recommended rosiglitazone be taken off the market, but an FDA panel disagreed, and it remains available in the U.S. From November 2011 until November 2013, the federal government did not allow Avandia to be sold without a prescription from a certified doctor; moreover, patients were required to be informed of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies. In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open label randomized control trial), which failed to show the heart infarct risks associated with the drug.In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks. It was withdrawn from the market in the UK and India in 2010, and in New Zealand and South Africa in 2011.
  • Rosiglitazona (maleato) é um fármaco da classe dos antidiabéticos. Teve sua venda proibida na Europa pela EMEA e nos Estados Unidos a venda foi restrita, pelos riscos cardiovasculares que apresenta.No Brasil a Anvisa determinou a retirada do medicamento das farmácias e drogarias, cancelando seu registro em 29 de setembro de 2010.
  • Vorlage:Infobox Chemikalie/Summenformelsuche vorhandenRosiglitazon ist ein Antidiabetikum aus der Gruppe der Insulin-Sensitizer zur Behandlung des Diabetes mellitus Typ 2. Das Wirkprinzip ist eine Erhöhung der Empfindlichkeit des Gewebes auf Insulin. Das körpereigene Insulin ist folglich wieder effektiver in der Lage, erhöhte Blutzuckerspiegel zu senken.Seit November 2010 ruht auf Anordnung des Bundesinstituts für Arzneimittel und Medizinprodukte (BfArM) in Deutschland die Verkehrsfähigkeit für Arzneimittel mit dem Wirkstoff Rosiglitazon. Ihr Nutzen-Risiko-Verhältnis war seitens des Ausschusses für Humanarzneimittel (CHMP) bei der Europäischen Arzneimittelagentur als insgesamt ungünstig eingestuft worden (kardiovaskuläre Risiken, gehäufte Herzinfarkte). Neuere Studien zeigen jedoch, dass die ursprünglichen Bedenken möglicherweise unbegründet sind, laut einer Überprüfung erhöht Rosiglitazon (Handelsname Avandia) das Herzinfarktrisiko nicht. Die Rohdaten seien in der Originalstudie, die zusätzlich nicht verblindet war, mehr oder weniger bewusst manipuliert worden. Das wirtschaftliche Interesse an der neuerlichen Vermarktung des Medikaments ist aktuell jedoch gering, da das Patent bereits ausgelaufen ist.Rosiglitazon scheint den herkömmlichen Antidiabetika bei höheren Kosten nicht überlegen zu sein.
  • Rosiglitazon, insüline karşı duyarlılığı artırarak anti-hiperglisemik etki gösteren tiyazolidindion sınıfından bir antidiyabetik ilaç. İlaçlarda, rosiglitazon maleat şeklinde kullanılır.
dbpedia-owl:depictionDescription
  • ÉnantiomèreS de la rosiglitazone (à gauche) et R-rosiglitazone (à droite)
dbpedia-owl:inchi
  • 1/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
dbpedia-owl:smiles
  • c1cc(N(C)CCOc2ccc(cc2)C[C@@H]2C(NC(S2)=O)=O)ncc1
dbpedia-owl:thumbnail
dbpedia-owl:wikiPageID
  • 587549 (xsd:integer)
dbpedia-owl:wikiPageLength
  • 13035 (xsd:integer)
dbpedia-owl:wikiPageOutDegree
  • 27 (xsd:integer)
dbpedia-owl:wikiPageRevisionID
  • 111052459 (xsd:integer)
dbpedia-owl:wikiPageWikiLink
prop-fr:c
  • 18 (xsd:integer)
prop-fr:h
  • 19 (xsd:integer)
prop-fr:inchi
  • 1 (xsd:integer)
prop-fr:legende
  • Énantiomère S de la rosiglitazone et R-rosiglitazone
prop-fr:n
  • 3 (xsd:integer)
prop-fr:nom
  • Rosiglitazone
prop-fr:o
  • 3 (xsd:integer)
prop-fr:s
  • 1 (xsd:integer)
prop-fr:smiles
  • c1ccncc1
prop-fr:tailleimage
  • 200 (xsd:integer)
prop-fr:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • La rosiglitazone, commercialisée sous le nom d'Avandia (r), fait partie d'une classe d'antidiabétique oral apparue sur le marché en 2002 : les thiazolidinediones.Son autorisation de mise sur le marché (AMM) a été suspendue en France et en Europe en septembre 2010 en raison d'importants risques cardiovasculaires.
  • Rozyglitazon (roziglitazon, rosiglitazon, rosiglitazone ATC A10BG) – należący do doustnych leków hipoglikemizujących (grupa tiazolidinedionów), lek stosowany w leczeniu cukrzycy.
  • Росиглитазон — лекарственное средство, гипогликемический препарат из группы тиазолидиндионов, селективный агонист ядерных рецепторов PPAR-гамма.
  • Rosiglitazona (maleato) é um fármaco da classe dos antidiabéticos. Teve sua venda proibida na Europa pela EMEA e nos Estados Unidos a venda foi restrita, pelos riscos cardiovasculares que apresenta.No Brasil a Anvisa determinou a retirada do medicamento das farmácias e drogarias, cancelando seu registro em 29 de setembro de 2010.
  • Rosiglitazon, insüline karşı duyarlılığı artırarak anti-hiperglisemik etki gösteren tiyazolidindion sınıfından bir antidiyabetik ilaç. İlaçlarda, rosiglitazon maleat şeklinde kullanılır.
  • Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride.
  • Vorlage:Infobox Chemikalie/Summenformelsuche vorhandenRosiglitazon ist ein Antidiabetikum aus der Gruppe der Insulin-Sensitizer zur Behandlung des Diabetes mellitus Typ 2. Das Wirkprinzip ist eine Erhöhung der Empfindlichkeit des Gewebes auf Insulin.
rdfs:label
  • Rosiglitazone
  • Rosiglitazon
  • Rosiglitazon
  • Rosiglitazona
  • Rosiglitazone
  • Rozyglitazon
  • Росиглитазон
owl:sameAs
http://www.w3.org/ns/prov#wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
foaf:name
  • Rosiglitazone
is dbpedia-owl:wikiPageRedirects of
is dbpedia-owl:wikiPageWikiLink of
is foaf:primaryTopic of